Summit Therapeutics Inc. (SMMT) Comparison with companies in other sectors?

Summit Therapeutics Inc. has a share price of 742.67M. You can analyze Summit Therapeutics Inc. (SMMT) competitors across different market sectors through stock heatmaps.

What are SMMT's NET and operating margins?

Summit Therapeutics Inc. (SMMT) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does SMMT's earnings per share (EPS) trend reflect its financial momentum?

Summit Therapeutics Inc. (SMMT) EPS is -0.34 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Summit Therapeutics Inc. is -84.32, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Summit Therapeutics Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Summit Therapeutics Inc. like P/E which is -88.40, P/B which is 61.81, and PEG which is 9.13. Compare them with sector averages to evaluate if the stock is priced fairly.

Summit Therapeutics Inc.

SMMT•NASDAQ

Healthcare

Biotechnology

$28.67

$1.10(3.99%)

Fundamental Analysis of Summit Therapeutics Inc. (SMMT)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.34

P/E Ratio

-84.32

ROE

-0.70%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$21.29B

Shares OutstandingTotal number of shares issued

$742.67M

Book Value/ShareNet worth per share

$0.47

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.34

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-70.50%

ROAReturn on total assets

-62.73%

ROCEReturn on capital employed

-48.29%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.24

Cash/ShareCash and equivalents per share

$0.49

FCF YieldFree cash flow as percentage of market cap

-0.82%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SMMTFinancial Ratios Analysis details for SMMT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SMMTSector Benchmarking details for SMMT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Summit Therapeutics Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Summit Therapeutics Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Summit Therapeutics Inc.'s unique business strengths and challenges.

Key Financial Metrics for Summit Therapeutics Inc.

For Summit Therapeutics Inc., essential financial indicators include EPS -0.34, PE -84.32, and ROE -0.70. These key ratios reveal insights into Summit Therapeutics Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Summit Therapeutics Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Summit Therapeutics Inc.

Metrics like Net Margin - and ROA -62.73% shed light on how well Summit Therapeutics Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Summit Therapeutics Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Summit Therapeutics Inc.

Using ratios such as P/B Ratio 61.81 and PEG Ratio 9.13, investors can assess whether Summit Therapeutics Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Summit Therapeutics Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Summit Therapeutics Inc.

Financial health indicators, such as Debt/Equity Ratio 0.02 and Cash Flow $-0.24, provide a snapshot of Summit Therapeutics Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Summit Therapeutics Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Summit Therapeutics Inc.

Investing in Summit Therapeutics Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Summit Therapeutics Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;